Section Review—Central & Peripheral Nervous Systems: Pre-Clinical Pharmacology of New Atypical Antipsychotics in Late Stage Development

References

• CASEY DE: What makes a neuroleptic atypical? In: Novel Antipsychotic Drugs. Meltzer HY (Ed.). Raven Press, Ltd., New York (1992):241–251. Good review on mechanisms of action of atypical antipsychotics.
   Google Scholar
• LIEBERMAN JA: Understanding the mechanism of action of atypical antipsychotk drugs. British!. Psychiatry(1993)163\(Suppl. 22):7–18. Good review on mechanisms of action of atypical antipsychotics. Includes drugs in use and in development.
   Google Scholar
• ELLENBROEK B: Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Thar-mac Ther. (1993) 57:1-78. Comprehensive review article on schizophrenia and antipsychotics. Describes pre-clinical tests for predicting antipsychotic activity and side effects.
   Google Scholar
• MELTZER H: The importance of serotonin-dopamine interactions in the action of clozapine. British]. Psychia-try (1992) 160:22-29. Good review on particular mechanism of action of clozapine.
   Google Scholar
• MELTZER HY, DANIELS S, FANG VS: Clozapine increases rat serum prolactin levels. Life Sciences (1975) 17:339-342. Seminal paper.
   Google Scholar
• MELTZER H: The mechanism of action of clozapine in relation to its clinical advantages. In: Novel AntipsychoticDrugs. Meltzer HY (Ed.). Raven Press, Ltd., New York (1992):1–13. Good review on clozapine.
   Google Scholar
• CHIODO LA, BUNNEY BS: Typical and atypical neuroleptics: differential effects of chronic administration onthe activity of A9 and A10 midbrain dopaminergic neurons. Neuroscience (1983) 3:1607-1619. Well cited paper on depolarisation inactivation studies with antipsy-chotics.
   Google Scholar
• WHITE FJ, WANG RY: Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamineneurons. Science (1983) 221:1054-1057. Well cited paper on depolarisation inactivation studies with antipsy-chotics.
   Google Scholar
• SKARSFELDT T: Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbraindopamine neurons in rats: acute and repeated treat-ment. Synapse (1992) 10:25-33. Sertindole electrophysiology.
   Google Scholar
• CASEY DE, GERLACH J, CHRISTENSSON E: Dopamine, acetylcholine, and GABA effects in acute dystonia in primates. Psychopharmacology (1980) 70:83–87.
   PubMed Web of Science ®Google Scholar
• CASEY DE: Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (1989) 99:S47–S53.
   PubMed Web of Science ®Google Scholar
• MIGLER BM, WARAWA EJ, MALICK JB: SEROQUEL: behav- ioral effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology (1993) 112:299-307. SEROQUEL behavioural pharmacology.
   Google Scholar
• SALLER CF, SALAMA Al: SEROQUEL: biochemical profile of a potential atypical antipsychotic. Psychopharmacol-ogy (1993) 112:285-292. SEROQUEL biochemical pharmacology.
   Google Scholar
• GOLDSTEIN JM, LITWIN LC, SUTTON EB, MALICK JB: SEROQUEL: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology (1993) 112:293-298. SEROQUEL electrophysiology.
   Google Scholar
• MOORE NA, CALLIGARO DO, WONG DT, BYMASTER F, TYE NC: The pharmacology of olanzapine and other new antipsychotic agents. Curr. Opin. Invest. Drugs (1993) 2:281–293•
   Google Scholar
• MOORE NA, TYE NC, AXTON MS, RISIUS FC: The behav- ioral pharmacology of olanzapine, a novel 'atypical' antipsychotic drug. J. Pharmacol. Exp. Ther. (1992) 262:545-551. Olanzapine behavioural pharmacology,
   Google Scholar
• STOCKTON ME, RASMUSSEN K: A comparison of °Ian-zapine and clozapine effects on dopamine neuronalactivity. Society for Neuroscience Abstracts (1993) 19:383. Olanzapine electrophysiology.
   Google Scholar
• GOLDSTEIN Jim, SNYDER DH: Effects of SEROQUELTm clozapine and other putative atypical agents in primatemodels of EPS. Schizophrenia Bulletin (1995). In press. Comparative pharmacology study with atypical antipsychotics in primate.
   Google Scholar
• DE BOER T, TONNAER ADM, DE VOS CJ, VAN DELFT AML: Neurochemical studies with the potential antipsychotic compound trans-5 chloro-2-methy1-2,3,3a,12b-tetrahy-dro-1H-dibenz [2,3:6,7] oxepino [4,5-c] pyrrolidine maleate. Arzneim-Forsch/Drug Res. (1990) 40:550-554. ORG 5222 neurochemistry.
   Google Scholar
• BROEKKAMP CLE, DE GRAAF JS, VAN DELFT AML: Behav-ioral pharmacology of trans-5 chloro- 2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino [4,5-c] pyrrolidine maleate, a compound interacting with dopaminergic and serotonergic receptors. Arzneim-Forsch/Drug Res. (1990) 40:544-549. ORG 5222 behavioural pharmacology. 17.
   Google Scholar
• ROOM P, TIELEMANS AIPC, DE BOER T, VAN DELFT AML,TONNAER JADM: The effect of the potential antipsy-chotic ORG 5222 on local cerebral glucose utilization in freely moving rats. Eur.J. Pharmacol. (1991) 205:233–240.
   PubMed Web of Science ®Google Scholar
• DE BOER T, BERENDSEN H, BROEKKAMP CLE, VRI-JMOEDDE VRIES MC, VOS RME, TONNAER JADM, VAN DELFT AML: Org-5222. Drugs of the Future (1993) 18:1117–1123.
   Google Scholar
• LEYSEN JE, GOMIVIEREN W, EENS A, DE CHAFFOY DE •COURCELLES D, STOOF JC, JANSSEN PAJ: Biochemical profile of risperickine, a new antipsychotic.J.Pharnzacol Exp. Ther. (1988) 247:661-670. Risperidone biochemical pharmacology.
   Google Scholar
• JANSSEN PAJ, NIEMEGEERS CJE, AWOUTERS F, •SCHELLEKENS KHL, MEGENS AAHP, MEERT TF: Pharma-cology of risperidone (R-64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic prop-erties. J. Pharmacol. Exp. Tber. (1988) 244:685-693. Risperidone behavioural pharmacology.
   Google Scholar
• HYTTEL J, ARNT J, MEIER E, SANCHEZ C, SKARSFELDT T: Effect of chronic neuroleptic treatment on spontane-ously active dopamine neurones in the A9 and A10 area of rat brain: correlation to receptor profile? Schizophre-nia Res. (1990) 3:50–51,
   Google Scholar
• CARPENTER WT, BUCHANAN RW: Letter to the editor. New Engl. j Med. (1994) 331:276.
   PubMedGoogle Scholar
• SANCHEZ C, ARNT J, DRAGSTED N, HYITEL J, LEMBOL H, MEIER E, PERREGAARD J, SKARSFELDT T: Neurochenaical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev. Res. (1991) 22:239-250. Sertindole neurochemical and behavioural pharmacology.
   Google Scholar
• SEEGER TF, SCHMIDT AW, LEBEL LA, KOE BK, ZORN SH, SCHULZ DW, IIOWARD HR, HEYM JH: CP88,059: a new antipsychotic drug with mixed dopamine D2 and sero-tonin 5-HT2 antagonist activities. Society for Neuroscience Abstracts (1993) 19:1623. Ziprasidone.
   Google Scholar
• SEYMOUR PA, SEEGER TF, GUANOWSKY V, ROBINSONGL, HOWARD H, HEYM J: Behavioral pharmacology of • CP-88,059: a new antipsychotic with both 5-HT2 and D2 antagonist activities. Society for Neuroscience Abstracts (1993) 19:1623, Ziprasidone.
   Google Scholar